APA
Click to copy
Foster, M. J., Shaia, J. K., Maatouk, C. M., Urbano, C. A., Bui, M. T., Hom, G. L., … Talcott, K. E. (2023). Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment. Ophthalmic Surgery Lasers and Imaging Retina.
Chicago/Turabian
Click to copy
Foster, Michael J., Jacqueline K. Shaia, Christopher M. Maatouk, Catherine A. Urbano, Mark T Bui, Grant L. Hom, B. L. Kuo, Rishi P. Singh, and Katherine E. Talcott. “Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment.” Ophthalmic Surgery Lasers and Imaging Retina (2023).
MLA
Click to copy
Foster, Michael J., et al. “Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment.” Ophthalmic Surgery Lasers and Imaging Retina, 2023.
BibTeX Click to copy
@article{michael2023a,
title = {Long-Term Visual Outcomes in Neovascular Age-Related Macular Degeneration Eyes With Baseline Macular Atrophy on Anti-Vascular Endothelial Growth Factor Treatment.},
year = {2023},
journal = {Ophthalmic Surgery Lasers and Imaging Retina},
author = {Foster, Michael J. and Shaia, Jacqueline K. and Maatouk, Christopher M. and Urbano, Catherine A. and Bui, Mark T and Hom, Grant L. and Kuo, B. L. and Singh, Rishi P. and Talcott, Katherine E.}
}
BACKGROUND AND OBJECTIVE This study explores the connection between macular atrophy (MA) status at baseline and best visual acuity (BVA) after 5 to 7 years of anti-vascular endothelial growth factor (anti-VEGF) injections on eyes with neovascular age-related macular degeneration (nAMD).
PATIENTS AND METHODS This retrospective study included patients with neovascular age-related macular degeneration receiving anti-VEGF injections at least twice-yearly for 5+ years at Cole Eye Institute. Analyses of variance and linear regressions explored the connection between MA status, baseline MA intensity, and 5-year BVA change.
RESULTS Of 223 included patients, 5-year BVA change was not statistically significant between MA status groups or from baseline. The population's average 7-year BVA change was -6.3 Early Treatment Diabetic Retinopathy Study letters. Type and frequency of anti-VEGF injections were comparable between MA status groups (P > .05).
CONCLUSION Regardless of MA status, 5- and 7-year BVA change lacked clinical relevance. If receiving regular treatment for 5+ years, patients with baseline MA achieve comparable visual outcomes to those without MA, with similar treatment and visit burdens. [Ophthalmic Surg Lasers Imaging Retina 2023;54(X):X-X.].
